CD274 and neoplasm: By means of the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA, United States) and characterized by the CPS, defined as the number of PD-L1-positive cells (tumor cells, lymphocytes, and macrophages) divided by total number of tumor cells × 100.2. PD-L1-positive tumors are classified as CPS of 1 or more and CPS of 10 or more, and PD-L1-negative tumors are classified as CPS less than 1